References
- Santos G. W., Tutschka P. J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukaemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 1983; 309: 1347–1352
- Nevill T. J., Barnett M. J., Kungemann H. G., Reece D. E., Shepherd J. D., Phillips G. L. Regimen‐related toxicity of busulfan‐cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J. Clin. Oncol. 1991; 9: 1224–1232
- Rosenthal M. A., Grigg A. P., Sheridan W. P. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non‐hemo‐poietic toxicity. Leuk. Lymphoma 1994; 14: 279–283
- Clift R. A., Buckner C. D., Thomas E. D., et al. Marrow transplantation for chronic myeloid leukaemia: A randomised study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blond 1994; 84: 2036–2043
- Kusnierz‐Glaz C. R., Coghlin T., Schlegel P. G., et al. Impact of admission body weight and dose adjusting in outcome of 500 patients with hematological malignancies post autologous transplantation. Blood 1995; 86, abstract no. 1590
- Zarowitz B. J., Peterson E., Popovich J. Relationship of bioelectrical impedance to pharmacokinetic parameters of theophylline in health males. Clin. Pharmacokinel. 1989; 17: 200–207
- Martin E. S., Crismon M. L., Godley P. L. Postinduction carbamazepine clearance in a adult psychiatric population. Pharmacotherapy 1991; 11: 296–302
- Hassan M., Oberg G., Ehrsson H., et al. Pharmacokinetic and metabolic studies of high‐dose busulphan in adults. Eur. J. Clin. Pharmacol. 1989; 36: 525–530
- Bray G. A. Overweight is risking fate: definition, classification, prevalence and risks. Ann. NY Acad. Sci. 1987; 499: 14–28
- Lukasi H. C., Johnson P. E., Bolonchuk W. W., Lykken G. I. Assessment of fat‐free mass using BI measurements of the human body. Amer. J. Clin. Nutrition 1985; 41: 810–817
- Roubenoff R., Kehayias J. J. The meaning and measurement of lean body mass. Nutrition Reviews 1991; 49: 163–175
- Roberts C. J. C., Jackson L., Halliwell M., Branch M. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobaritone administration in man. Br. J. Clin. Pharmac 1976; 3: 907–913
- Angus P. Department of Gastroenterology, Austin Repatriation Medical Centre, Heidelberg, VictoriaAustralia, personal communication
- Grochow L. B. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Sem. Oncol. 1993; 20: 18–25
- Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150
- Dix S. P., Multins R. E., Jerkunica I., et al. Association of busulfan area under the curve (AUC) with veno‐occlusive disease (VOD) following bone marrow transplantation (BMT). Blood 1993; 82: 418a, abstract no. 1658
- Schuler U., Schroer S., Kuhnle A., et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?. Bone Marrow Transplant 1994; 14: 759–765
- Hassan M., Oberg G., Bjorkholm M., Wallin I., Lindgren M. Influence of prophylactic anticonvulsant therapy on high‐dose busulphan kinetics. Cancer Chemo. Pharmacol. 1993; 33: 181–186
- Kasaim Kiyama Y., Watanabe M., et al. Toxicity of high‐dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation. Transplant. Proc. 1992; 24: 1529–1530
- Storb R., Deeg H. J., Whitehead J., et al. Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft‐vs‐host disease after marrow transplantation for leukaemia. New Engl. J. Med. 1986; 314: 729–735